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Abstract
Introduction: Preeclampsia is one of the most serious diseases of the second half of pregnancy and is surely amongst 
the top three causes of maternal mortality. Therefore, the creation of new drugs for preventing and correcting pre­
eclampsia is an urgent task.
Methods: In the experiment, an ADMA-like L-NAME-induced model of preeclampsia was reproduced. To assess the 
emerging morphofunctional disorders, the following parameters were used: blood pressure, endothelial dysfunction coef­
ficient, microcirculation in the placenta, proteinuria, fluid content in the large omentum, concentration of terminal metab­
olites in the blood plasma, morphological state of the placenta and kidneys and morphometric parameters of the foetus.
Results and Discussion: Injection of L-NAME into the animals from the 14th to the 20th day of pregnancy causes dis­
orders: an increase in systolic and diastolic blood pressure by 1.4 and 1.5 times, an increase in proteinuria by 3.3 times 
and an increase in the fluid content in a large omentum from 45.82 ± 1.82% to 54.73 ± 1.96%, which correspond to 
disorders due to preeclampsia in pregnant women. There was also a disturbance of endothelial function, as evidenced 
by an increase in the coefficient of endothelial dysfunction (CED) by 2.9 times. The use of resveratrol leads to a pro­
nounced correction in the changes that occur: a decrease in systolic and diastolic arterial pressure by 1.2 and 1.3 times, a 
decrease in proteinuria by a factor of 1.9 and a decrease in the fluid content in the large omentum to 50.00 ± 1.25%. The 
use of nicorandil leads to a pronounced correction in the resulting changes: a decrease in the diastolic blood pressure by 
1.14 times, a decrease in proteinuria by a factor of 1.7 and a decrease in the fluid content in the large omentum to 50.57 
± 2.08%. CED decreased 1.7 times. When combining their use with amlodipine, the positive effects increased: systolic 
and diastolic blood pressure decreased 1.13 and 1.24 times and 1.14 and 1.23 times, respectively, proteinuria decreased 
2.7 and 2.3 times, the fluid content in the large omentum was reduced to 44.54 ± 1.80% and 46.73 ± 1.30%. CED 
decreased 1.7 and 2.3 times. The administration of glibenclamide together with resveratrol and nicorandil removes a 
significant part of their positive effects.
Conclusion: Resveratrol and nicorandil have a significant positive effect in the correction of morphofunctional disor­
ders in animals with ADMA-like preeclampsia. Activation of K+ATP channels plays a significant role in the realisation 
of their positive effects.
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Introduction
Preeclampsia is a multisystem, highly variable and preg­
nancy-specific condition that occurs after the 20th week of 
gestation and is determined by the presence of arterial hy­
pertension and proteinuria. For many years, preeclampsia 
has been one of the frequent and threatening complicati­
ons of pregnancy and childbirth, leading to disability of 
mothers and their children (Gureev et al. 2014, Kolgush- 
kina 2000, Reznikova 2013, Shuvalov et al. 2014, Save­
lyeva et al. 2011, Federal State Statistics Service).
According to the Ministry of Healthcare of the Russi­
an Federation, over the past decade, hypertensive com­
plications in pregnancy have been ranked third in the list 
of causes of maternal mortality and, in 2014, accounted 
for 15.7% of the structure of maternal losses, in 2015 
-  10.2% and by the end of 2016, this figure was 11.7% 
(Shuvalov et al. 2014, Methodical letter 2016).
According to the statistics, the frequency of pree­
clampsia in pregnant women has increased in recent years 
and ranges from 7% to 20% (Kolgushkina 2000, Reznik­
ova 2013, Shuvalov et al. 2014, Federal State Statistics 
Service, Methodical letter 2016).
Perinatal morbidity is 56% and perinatal mortality is 
3-4 times higher than that of the population, reaching 
12% (Savelyeva et al., 2011).
The etiological aspects of preeclampsia development 
still provoke heated discussions in the scientific commu­
nity. There are several theories of preeclampsia develop­
ment: the immunity theory, the theory of disadaptation, 
the theory of placental ischemia, the hormonal theory, the 
theory of toxic effects, the hereditary theory, etc. (Shu­
valov et al. 2014, Savelyeva et al. 2011, Sidorova 2003).
With regard to the pathogenesis of preeclampsia, although 
a large number of uncertainties remain, its main conditions 
are determined and all the newly discovered information 
complements pathological events. It is generally accepted 
that the obligatory component of the pathogenesis of pree­
clampsia is endothelial dysfunction (Bloshhinskaja 2003, 
Gureev 2012, Scioscia et al. 2015, Sanchez-Aranguren et 
al. 2014). Endothelium, or internal cellular lining of vessels, 
provides selective permeability between intravascular and 
interstitial space, whichis ensuredby its specific structure.
A histological study of the placenta in females with 
preeclampsia revealed incomplete invasion of the cytotrop- 
hoblast into the spiral arteries of the mother. The level of 
maturity of the spiral arteries themselves in cases of pree­
clampsia does not reach the level of normal pregnancy (Pe­
reira et al. 2015, Verlohren et al. 2010, Ducray et al. 2011). 
This leads to ischemia of the trophoblast and an increase in 
the permeability of the foetoplacental barrier (Ducray et al. 
2011, vanOppenraaij etal. 2011, Wangetal. 2015).
The response to ischemia is the formation of a large 
number of vasoactive humoral factors; besides, foetal an­
tigens entering the bloodstream of the mother are likely to 
cause the accumulation of methylated analogues of L-argi- 
nine (ADMA, MMA) in the plasma. The latter causes dys­
function of the endothelium, secondary ischemic lesions
and oxidative stress (Sidorova 2003, Bloshhinskaja 2003, 
Sanchez-Aranguren et al. 2014, Bloshchinskaja 2003). 
The consequence of the described events is a decrease in 
the formation of nitric oxide, which has not only a vasodi­
lating effect, but also suppresses apoptosis in the placenta 
and plays a significant role in the realisation of the effects 
of many growth factors. Thus, the vicious circle closes: 
angiogenesis abnormality provokes placenta ischemia and 
placental ischemia aggravates angiogenesis abnormality.
The described spectrum of pathogenetic mechanisms 
of pathogenesis, which is far from being complete, shows 
that this disease is associated with the emergence of se­
veral vicious circles, the integral components of which 
are endothelial dysfunction and ischemia of the placenta.
Earlier in our laboratory, the endoteleoprotective 
properties of resveratrol and nicorandil (Danilenko 2013, 
Kochkarov 2009, Kochkarov et al. 2006, Kochkarov 
2008) were studied which could activate K+ATP channels 
(Tanaka et al. 2010, Novakovic et al. 2015); therefore we 
considered them to be the most promising for our studies.
Objective
To experimentally substantiate the prospects of using 
drugs which activate K+ATP channels: resveratrol and ni­
corandil in correcting morphofunctional disorders of ex­
perimental preeclampsia.
Methods
The experiment was performed on 250 white Wistar fema­
le rats weighing 250-300 g. To form the groups of preg­
nant animals with predetermined periods, the females (3 
animals), which had been kept separately, were caged with 
males (2 animals) for 24 hours. Then the animals were se­
parated and, 10 days later, in the condition of etheric sleep, 
determined pregnancy by palpation. In our experiments, 
pregnancy occurred in 30-40%. An ADMA-like agent, 
a non-selective NO-synthase blocker, N-nitro-L-arginine 
methyl ester (L-NAME), was administered intraperito- 
neally at a dose of 25 mg/kg/day for seven days (14-20 
days of gestation). According to literature, this moderately 
prolonged average dose regimen of L-NAME administra­
tion results in the blockade of NO-synthase in the endot­
helium of the placental vessels, which leads to destructive 
changes in placental tissues, arterial hypertension and pro­
teinuria (Gureev et al. 2014, Gureev 2012, Tsukimori et 
al. 2008). On the 21st day of pregnancy, under anaesthesia 
(chloral hydrate 300 mg/kg), a catheter was inserted into 
the left carotid artery to record haemodynamic parameters 
and bolus administration of pharmacological agents was 
performed in the right femoral vein. The haemodynamic 
parameters: systolic blood pressure (SBP), diastolic arteri­
al pressure (DBP) and heart rate (HR) were measured con­
tinuously by means of a sensor and a hardware complex 
for invasive measurement of haemodynamic parameters
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of Biopac (USA) and by the computer programme Asq- 
Knowledge 3.8.1 (Gureev et al. 2014, Gureev 2012).
The degree of endothelial dysfunction in the experi­
mental animals was assessed by the ratio of indices of 
endothelium-dependent vasodilation and endothelium-in­
dependent vasodilation with subsequent calculation of the 
coefficient of endothelial dysfunction (CED) (Korokin 
et al. 2011, Pokrovsky et al. 2006).
The level of NO metabolites (the total concentration of 
nitrates and nitrites, NOx) was determined by the colori­
metric method for the development of colour in the diazo- 
tisation reaction by sulphonamide nitrite, which is part of 
the reagent (Metelskaya et al. 2004, Oganov et al. 2004).
Measurement of microcirculation in the placenta was 
carried out with the help of Biopacsystems equipment: 
MP100 polygraph with LDF100C laser doppler flow- 
metry module (LDF100C) and invasive needle probe 
TSD144 [1, 25], which was mounted directly on to the 
placental disc projection. LDF was recorded and proces­
sed using the AcqKnowledge version 3.8.1. The microcir­
culation values were expressed in perfusion units (PEU).
Collection of urine was carried out within 12 hours with 
the use of special metabolic cells. Determination of the 
amount of protein in daily urine was carried out using the 
pyrogallol red method on a spectrophotometer PE-5400B.
To study the liquid content in the large omentum, it 
was weighed, followed by drying at 37°C for 24 hours 
and re-weighing (Reznikova 2013, Ivanova et al. 2012).
For the morphological confirmation of the development 
of the simulated pathological processes and for the com­
plex evaluation of the efficacy of the preparations, a his­
tological examination (in all series of the experiment) of 
kidneys and placenta was carried out. The material is fixed 
in 10% formalin, followed by pouring into paraffin. Sec­
tions of the kidneys were taken perpendicular to the main 
axis of the organ through the pelvis. Histological sections 
of the placenta were made in a strictly vertical direction 
through the middle of the placental disc with the capture of 
all layers of the placenta and the walls of the uterine horn. 
Microslide studies, photorecording and morphometry were 
performed on a Leica DM4000B microscope with a video 
registration and imaging system. For all morphological stu­
dies, staining with haematoxylin and eosin was used.
For subsequent statistical processing, the degree of 
morphological changes was ranked. The foetuses were re­
moved from the uterine cavity and weighed; their growth 
(craniocaudal size) was measured, followed by calcula­
ting the height-weight coefficient (Mironov 2012).
For all the data, descriptive statistics were applied: the 
data were checked for the normality of the distribution. 
The type of distribution was determined by the Shapi- 
ro-Wilk criterion. In the case of a normal distribution, the 
mean value (M) and the standard error of the mean (m) 
were calculated. The intergroup differences were analy­
sed by means of parametric (Student’s t-test) or nonpa­
rametric (Mann-Whitney test) methods, depending on 
the type of distribution. The statistical significance of the 
differences between the morphological changes after their
ranking was assessed using the Mann-Whitney analysis 
of nonparametric data (Glanz 1999, Sydorenko 2003). All 
the calculations were performed using the Microsoft Ex­
cel 7.0 statistical software package.
According to the objective, all the animals were distri­
buted amongst the following groups:
1. Control group (animals with oral administration of NaCl 
in equivalent doses from 14th to 20th days of pregnancy).
2. Modelling ADMA-like preeclampsia (animals with in­
traperitoneal administration of L-NAME at a dose of 25 
mg/kg once daily from 14th to 20th days of gestation).
3. Modelling ADMA-like preeclampsia + Amlodipine 
(0.5 mg/kg/day orally).
4. Modelling ADMA-like preeclampsia + Nicorandil 
(2x10 mg/kg/day orally).
5. Modelling ADMA-like preeclampsia + Resveratrol 
(2 mg/kg/day orally).
6. Modelling ADMA-like preeclampsia + Nicorandil 
(2x10 mg/kg/day orally) + Amlodipine (0.5 mg/kg/ 
day orally).
7. Modelling ADMA-like preeclampsia + Resveratrol (2 
mg/kg/day orally) + Amlodipine (0.5 mg/kg/day orally).
8. Modelling ADMA-like preeclampsia + Nicorandil 
(2x10 mg/kg/day orally) + Glibenclamide (50 mg/kg).
9. Modelling ADMA-like preeclampsia + Resveratrol (2 
mg/kg/day orally) + Glibenclamide (50 mg/kg).
Results and discussion: Effect 
o f resveratrol and nicorandil on 
morphofunctional disorders in 
ADMA-like preeclampsia.
The administration of resveratrol (2 mg/kg/day) to ani­
mals with experimental preeclampsia resulted in a statis­
tically significant (p <0.05) decrease in systolic and dia­
stolic blood pressure from 181.3 ± 4.58 and 144.7 ± 4.09 
m m Hgto 154.6± 7.53 and 110.90± 8.71 mmHg, respec­
tively, but the level of the intact animals was not reached 
(133.8 ±2.45 and95.36 ±2.82 mmHg, respectively). The 
administration of nicorandil (2x10 mg/kg/day) resulted in 
a statistically significant (p <0.05) decrease in only di­
astolic blood pressure, blood pressure reaching 174.1 ± 
6.14 and 126.9 ±6.31 mm Hg, respectively.
The ratio of endothelium-dependent vasorelaxation 
and endothelium-independent vasorelaxation, expressed 
by CED, was not influenced by resveratrol. Nicorandil 
statistically significantly reduced CED from 3.36 ± 0.23 
to 1.96 ± 0.13 (p <0.05), but not to the level of the intact 
animals (1.17 ± 0.10).
In the animals with ADMA-like preeclampsia, when res­
veratrol and nicorandil were administered, an increase in the 
microcirculation in the placenta was observed from 213.7 ± 
14.97 PUn to 452.4 ± 27.16 PUnand 377.9 ± 18.8 PUn, res­
pectively (p<0,05), which did not differ statistically from 
the level of the intact animals (409.9 ± 30.57 PUn).
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In the animals with ADMA-like preeclampsia, a statis­
tically significant (p<0.05) decrease in the concentration 
of final metabolites of NO in blood plasma was observed 
in comparison with the intact animals from 2.22 ± 0.08 
pmol/dl to 1.27 ± 0.04 pmol/dl. Using resveratrol and ni- 
corandil in the animals with ADMA-like preeclampsia, 
their statistically significant increase was observed to 1.78 
± 0.05pmol/dl and 1.80 ± 0.07 pmol/dl, respectively.
The administration of an ADMA-like agent to the 
pregnant animals from the 14th to 20th days of gestation 
resulted in an increase in proteinuria from 0.69 ± 0.70 
g/1 to 2.30 ± 0.14 g/1 (p<0.05). The administration of res­
veratrol and nicorandil to the animals with experimental 
preeclampsia resulted in a statistically significant decre­
ase in the urinary protein concentration to 1.22 ± 0.11 g/1 
and 1.39 ± 0.10 g/1, respectively (p<0.05).
A study of the fluid content in the large omentum of the 
animals with ADMA-like preeclampsia revealed its incre­
ase in comparison with the intact pregnant animals from 
45.82 ± 1.82% to 54.73 ± 1.96% (p<0.05). The adminis­
A
tration of resveratrol and nicorandil resulted in a decrease 
in the level of swelling in the tissues of the large omen­
tum to a level statistically indistinguishable in relation to
the intact pregnant animals -  50.00 ± 1.25% and 50.57 ± 
2.08%, respectively.
A morphological examination of the renal parenchyma 
in the animals with ADMA-like preeclampsia revealed: 
anaemia and spasm of renal vessels, thickening of their 
walls, thickening of the basement membrane of the glo­
meruli capillaries in the form of a wire loop (Fig. 1(B)). 
No noticeable reaction of mesangium was observed. 
Thus, the average number of cells per glomerulus in the 
group with experimental preeclampsia was 39.60 ± 1.88 
(in the normal condition 40.60 ± 2.39).
In the placenta of the animals with ADMA-like pree­
clampsia, massive deposition of fibrin and significant 
changes in ischemic genesis were observed (Fig. 2(B)).
The integral index of analysis of the morphological 
study in animals with ADMA-like preeclampsia was 5-6 
points (p <0.05).
B
Figure 1. Histological picture of the kidney in the modelling of ADMA-like preeclampsia. Note: (A) -  the glomerule of an intact 
animal. (B) the glomerule of an animal with ADMA-like preeclampsia. x200.
Figure 2. Histological picture of the placenta in the modelling of ADMA-like preeclampsia. Note: (A) type of intact placenta. 
(B) ADMA-like preeclampsia. Vacuolar degeneration of giant cell trophoblast; dystrophic changes in the decidual layer, foci of 
necrosis at the border of the giant cell trophoblast and decidual tissue. x200.
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The administration of resveratrol and nicorandil to the 
animals with ADMA-like preeclampsia led to significant 
positive morphological changes in the kidneys and placen­
ta. In the kidneys, less significant changes were recorded 
(Fig. 3(A)). There was no noticeable mesangium reaction 
(42.20 ± 1.91 cells when administering resveratrol and 
39.40 ± 1.53 cells when administering nicorandil). In the 
placenta, moderately significant fibrous deposits, less sig­
nificant dystrophic changes in the giant cell trophoblast 
and decidual layer and no necrosis foci were observed. 
The integral index of the analysis of the morphological 
study in the animals with the correction of ADMA-like 
preeclampsia by resveratrol and nicorandil was 3 points 
(p <0.05).
The study of the features of foetal development in the 
animals with ADMA-like preeclampsia revealed a mod­
erately significant foetal hypotrophy, which manifested 
itself in a decrease in mass and length (growth). It should 
be noted that the mass of the foetuses was most affect­
ed. With the administration of resveratrol, only the mass 
of the foetus decreased. With the administration of nico­
randil, neither the weight nor height indices differed from 
those of intact foetuses (Table 1).
Thus, the results of the series of experiments indicate 
a pronounced protective activity of resveratrol and nico- 
randil in the correction of morphofunctional disorders 
occurring in the animals when modelling ADMA-like 
preeclampsia.
Effect of resveratrol and nicorandil when combined 
with amlodipine on morphofunctional disorders in 
ADMA-like preeclampsia
The administration of nicorandil in combination with am- 
lodipine to the animals with experimental ADMA-like 
preeclampsia resulted in a statistically significant (p <0.05) 
decrease in systolic and diastolic blood pressure (Table 2). 
It should be noted that in monotherapy, statistically neither 
amlodipine nor nicorandil significantly reduced systolic 
pressure. Therefore, a decrease in systolic pressure with 
their combined use can be regarded as a potentiation of 
their action. Addition of amlodipine to resveratrol did not 
lead to an increase in its hypotensive effect.
The administration of resveratrol and nicorandil in com­
bination with amlodipine to the animals with ADMA-like 
preeclampsia led to a more significant decrease in CED, 
compared to the groups of animals where these pharmaco­
logical agents were used as monotherapy (Table 2).
The administration of resveratrol and nicorandil in 
combination with amlodipine to the animals with AD- 
MA-like preeclampsia led to an increase in the microcir­
culation in the placenta (p <0.05) (Fig. 4(A)).
In the biochemical study of the final metabolite con­
centration of NO in the blood plasma, their statistically 
significant increase (p <0.05) was recorded (Fig. 4(B)). 
The most significant effect was observed when amlodipi- 
ne was combined with nicorandil. In the animals of this
Figure 3. Morphological picture of kidneys and placenta in animals with correction of ADMA-like preeclampsia by resveratrol. 
Note: (A) kidney; (B) placenta. x200.
Table 1. Effect of Resveratrol and Nicorandil on the Height-weight Indices of Foetal Development in ADMA-like Preeclampsia (M 
±m; n  = 10).
Group Index Pregnant intact Pregnant + L-NAME Pregnant + L-NAME + Resveratrol
Pregnant + L-NAME + 
Nicorandil
1.68±0.09y 1.38±0.07* 1.45±0.06* 1.53±0.06
Foetus weight, g 23.79±0.42y 21.82±0.34* 22.59±0.61* 22.91±0.61
Foetus height, mm 14.01±0.28y 15.81±0.43* 15.58±0.35* 14.97±0.43
Notes: * - p<0.05 in comparison with intact pregnant females; y -p <  0.05 in comparison with L-NAME group.
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group, the microcirculation rate in the placenta was at the 
level of intact animals.
The administration of resveratrol and nicorandil in 
combination with amlodipine to the animals with ex­
perimental preeclampsia led to a statistically signifi­
cant decrease in urinary protein concentrations (p<0.05) 
(Fig. 4(C)).
The combined administration of amlodipine with 
resveratrol or nicorandil to the animals with ADMA-like 
preeclampsia resulted in reduced swelling of the large
omentum to a level statistically distinct when compared 
with “untreated” animals (Figure 4(D)).
The combined use of these drugs in the animals with 
ADMA-like preeclampsia led to significant positive mor­
phological changes in the kidneys and placenta. In the 
kidneys, there was a moderate vasospasm. No symptoms 
of the wire loop were observed (Fig. 5). There was no 
noticeable mesangium reaction (38.10 ± 2.23 cells and 
40.50 ± 2.33 cells, respectively) (in the normal condition 
40.60 ± 2.39 cells).
Table 2. Results of Correction of ADMA-like Preeclampsia with Resveratrol and Nicorandil in Combination with Amlodipine (M
±m;N=10) .
Group SBP mm Hg DBP mm Hg CED relative units
Intact 133.8±2.45у 95.36±2.82 у 1.17±0.10 у
L-NAME 181.3±4.58* 144.7±4.09* 3.36±0.23*
L-NAME + Amlodipine 167.0±7.67* 122.9±7.49у 2.24±0.19у
L-NAME +Resveratrol 154.6±7.53 y 110.90±8.71y 3.36±0.41*
L-NAME +Nichorondil 174.1±6.14* 126.9±6.31у 1.96±0.13у
L-NAME +Resveratrol+Amlodipine 159.9±4.36у 116.5±4.41у 2.02±0.19у
L-NAME +Nicorondil+Amlodipine 158.5±3.84y 117.2±3.70y 1.49±0.15у
Notes: SBP, DBP - systolic and diastolic blood pressure (mmHg); CED - coefficient of endothelial dysfunction (r.u.); * - p <0.05 in 
comparison with the group of intact animals; y - p<0.05 in comparison with the L-NAME group.
Figure 4. Effect of resveratrol and nicorandil in combination with amlodipine on microcirculation in the placenta, plasma NOx con­
tent, proteinuria and swelling of the large omentum with ADMA-like preeclampsia. Notes: * - p<0.05 in comparison with the group 
of intact animals; y - p<0.05 in comparison with the L-NAME group.
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In the placenta, weakly expressed fibrous deposits were 
observed; dystrophic changes of the giant cell trophoblast 
and decidual layer were not significantly expressed; there 
were no necrosis foci (Fig. 5). The integral index of the ana­
lysis of the morphological study in the animals with the cor­
rection of ADMA-like preeclampsia by resveratrol and ni- 
corandil in combination with amlodipine is given in Table 3.
A study of the features of foetal development in the 
animals with ADMA-like preeclampsia revealed no foetal 
hypotrophy when administering resveratrol and nicoran- 
dil in combination with amlodipine (Table 4).
Thus, the results of a series of experiments indicate a 
significant protective activity of resveratrol and nicorandil
A
when combined with amlodipine to correct morphofunc- 
tional disorders occurring in the animals when modelling 
ADMA-like preeclampsia. It should be noted that the 
combinations used have a more significant correction of 
morphofunctional disorders in comparison with the drugs 
used in monotherapy.
Role of K+ATP channels in the positive effects of res­
veratrol and nicorandil in ADMA-like preeclampsia.
The administration of resveratrol and nicorandil in com­
bination with an inhibitor of K+ATP channels to the ani­
mals with experimental ADMA-like preeclampsia led to
B
Figure 5. Morphological picture of kidneys and placenta in animals with correction of ADMA-like preeclampsia by nicorandil in 
combination with amlodipine. Note: (A) kidney; (B) placenta. x200.
Table 3. Effect of Resveratrol and Nicorandil in Combination with Amlodipine on Comprehensive Assessment of Pathomorpholog- 
ical Changes in Kidneys and Placenta in ADMA-like Preeclampsia (M ±m; n  = 10).
Series of experiments Comprehensive assessment in points
Pregnant intact 0-1y
Pregnant + L-NAME 5-6*
Pregnant + L-NAME + Amlodipine 4y
Pregnant + L-NAME + Resveratrol 3y
Pregnant + L-NAME + Nicorandil 3y
Pregnant + L-NAME + Resveratrol+ Amlodipine 2y
Pregnant + L-NAME + Nicorandil+ Amlodipine 1-2y
Notes: * - p<0.05 in comparison with intact pregnant females; y- p<0.05 in comparison with L-NAME group.
Table 4. Effect of Resveratrol and Nicorandil in Combination with Amlodipine 
in ADMA-like Preeclampsia ( M± m ; n =  10).
on Height-weight Indicators of Foetal Development
Group Indicator Foetus weight, g Foetus height, mm Height / weight, mm/g
Pregnant intact 1.68±0.09y 23.79±0.42y 14.01±0.28y
Pregnant + L-NAME 1.38±0.07* 21.82±0.34* 15.81±0.43*
Pregnant + L-NAME + Amlodipine 1.40±0.09* 22.09±0.40* 15.78±0.51*
Pregnant + L-NAME + Resveratrol 1.45±0.06* 22.59±0.61 15.58±0.35*
Pregnant + L-NAME + Nicorandil 1.53±0.06 22.91±0.61 14.97±0.43
Pregnant + L-NAME + Resveratrol+ Amlodipine 1.60±0.07y 23.19±0.53 14.49±0.48
Pregnant + L-NAME + Nicorandil+ Amlodipine 1.59±0.05y 22.92±0.53 14.42±0.53
Notes: * - p<0.05 in comparison with intact pregnant females; y - p<0.05 in comparison with L-NAME group.
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a decrease in the intensity of their positive effects. Thus, 
an increase in systolic and diastolic arterial pressure was 
observed in comparison with the groups of the animals in 
which resveratrol and nicorandil were used in monothera­
py (Table 5). It should be noted that the diastolic pressure 
in the group of the animals with combined administration 
of nicorandil and glibenclamide did not statistically differ 
from that in the group of the “untreated” animals.
The administration of nicorandil in combination with 
glibenclamide to the animals with ADMA-like pree­
clampsia led to an increase in CED, compared to the 
groups of the animals where nicorandil was used as a 
monotherapy (Table 5), but this coefficient continued to 
differ statistically significantly from that in the group of 
the “untreated” animals (p <0.05).
Adding glibenclamide to nicorandil and resveratrol 
when correcting ADMA-like preeclampsia led to redu­
ced microcirculation in the placenta to a level statistically 
distinct from that in the animals with correction by these 
drugs in the monotherapy (Fig. 6(A)) (p <0.05), while ad­
ding resveratrol almost completely removed its positive 
effect on microcirculation.
In a biochemical study of the concentration of terminal 
metabolites of NO in the blood plasma, a statistically sig­
nificant decrease in glibenclamide when using resveratrol 
and nicorandil to correct morphofunctional disorders in 
the animals with ADMA-like preeclampsia was revealed 
(Fig. 6(B)). Nevertheless, this indicator was at a level sta­
tistically different from that in the group of the “untrea­
ted” animals (p <0.05).
Adding glibenclamide to resveratrol and nicorandil 
caused an increase in proteinuria compared to the groups 
of the animals in which these pharmacological agents 
were used inthe monotherapy (Fig. 6(C)) (p<0.05).
The administration of resveratrol and nicorandil in 
combination with glibenclamide led to an increased 
swelling of the tissues of the large omentum to a level 
statistically indistinguishable when compared to that of 
the “untreated” animals (Fig. 6(D)).
The administration of resveratrol and nicorandil in 
combination with glibenclamide in the animals with AD- 
MA-like preeclampsia aggravated the morphological pat­
tern in the kidneys and placenta. In the kidneys, there was 
a pronounced spasm of the vessels. There were symptoms 
of a wire loop. There was no noticeable mesangium reac­
tion (40.20 ± 1.68 cells and 38.60 ± 1.63 cells, respective­
ly) (in the normal condition 40.60 ± 2.39 cells).
In the placenta, there were observed fibrous deposits; 
the dystrophic changes of the giant cell trophoblast and 
the decidual layer were not significantly expressed; there 
were isolated foci of necrosis. The integral index of the 
analysis of the morphological study in the animals with 
correction of ADMA-like preeclampsia by resveratrol and 
nicorandil affected by glibenclamide is given in Table 6.
Investigation of peculiarities of foetal development in 
the animals with ADMA-like preeclampsia revealed foe­
tal hypotrophy when administering resveratrol and nico- 
randil in combination with glibenclamide (Table 7). The 
mass of the foetus was most affected.
Thus, the results of the series of experiments conduc­
ted indicate a significant decrease in the positive effects 
of resveratrol and nicorandil by glibenclamide. Since 
glibenclamide is a blocker of K+ATP channels, the series 
of experiments makes it possible to assert the significant 
role of K+ATP in revealing protective effects of resver- 
atrol and nicorandil when correcting morphofunctional 
disorders in ADMA-like preeclampsia. Incomplete can­
cellation of their positive effects is due to the fact that
Table 5. Results of Correction of ADMA-like Preeclampsia with Resveratrol and Nicorandil Affected by Glibenclamide (M ± m; n = 10).
Group SBP mm Hg DBP mm Hg CED relative units
Intact 133.8±2.45y 95.36±2.82 y 1.17±0.10 y
L-NAME 181.3±4.58* 144.7±4.09* 3.36±0.23*
L-NAME + Resveratrol 154.6±7.53у* 110.90±8.71у 3.36±0.41*
L-NAME + Nicorandil 174.1±6.14* 126.9±6.31y 1.96±0.13y
L-NAME + Resveratrol + Glibenclamide 158.1±5.16у 120.8±3.16у 2.95±0.22*
L-NAME + Nicorandil + Glibenclamide 186.0±7.46* 134.5±8.92* 2.55±0.0.17y*
Notes: SBP, DBP -  systolic and diastolic blood pressure (mmHg); CED -  coefficient of endothelial dysfunction (r.u.); * - p<0.05 in 
comparison with the group of intact animals; y - p<0.05 in comparison with the L-NAME group.
Table 6. Effect of Resveratrol and Nicorandil Affected by Glibenclamide on the Comprehensive Assessment of Pathomorphological 
Changes in Kidneys and Placenta in ADMA-like Preeclampsia (M ± m;n = 10).
Series of experiments Comprehensive assessment in points
Pregnant intact 0-1y
Pregnant + L-NAME 5-6*
Pregnant + L-NAME + Resveratrol Зу
Pregnant + L-NAME + Nicorandil 3y
Pregnant + L-NAME + Resveratrol + Glibenclamide 4y
Pregnant + L-NAME + Nicorandil + Glibenclamide 4-5y
Notes: * - p<0.05 in comparison with pregnant intact females; y- p<0.05 in comparison with L-NAME group.
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resveratrol and nicorandil have a pronounced biological 
activity in their implementation in which K+ATP channels 
do not participate.
Conclusion
The administration of a nonselective inhibitor of NOS - 
L-NAME resulted in an increased systolic and diastolic 
pressure, a disrupted relationship between endothelium-de­
pendent and endothelium-independent vasodilating reacti­
ons, a reduced microcirculation in the placenta, a decreased
concentration of terminal metabolites of NO in the blood 
plasma, increased proteinuria, an increased fluid content 
in the large omentum, disorders in the placenta of ische­
mic origin and foetal hypotrophy. The described symptom 
complex of morphofunctional changes quite accurately 
represents the clinical picture of syndromes arising during 
preeclampsia. Thus, ADMA-like preeclampsia fully mat­
ches the model chosen for our experiment.
The administration of resveratrol led to a statistically 
significant decrease in systolic and diastolic arterial pres­
sure, an increase in microcirculation in the placenta, a de­
crease in the protein content in the urine, swelling of the
Figure 6. Effect of resveratrol and nicorandil in combination with glibenclamide on microcirculation in the placenta, proteinuria, 
plasma NOx concentration and swelling of the large omentum with ADMA-like preeclampsia. Notes: * - p<0.05 in comparison with 
the group of intact animals; y- p<0.05 in comparison with L-NAME group.
Table 7. Effect of Resveratrol and Nicorandil in Combination with Glibenclamide on the Height-weight Foetal Development Indi­
cators in ADMA-like Preeclampsia (M ±m;n=10) .
Group Indicator Foetus weight, g Foetus height, mm Height / weight, mm/g
Pregnant intact 1.68±0.09y 23.79±0.42y 14.01±0.28y
Pregnant +L-NAME 1.38±0.07* 21.82±0.34* 15.81±0.43*
Pregnant + L-NAME + Resveratrol 1.45±0.06* 22.59±0.61* 15.58±0.35*
Pregnant +L-NAME + Nicorandil 1.53±0.06* 22.91±0.61* 14.97±0.43*
Pregnant + L-NAME + Resveratrol + Glibenclamide 1.44±0.09* 22.05±0.67* 15.31±0.54*
Pregnant + L-NAME + Nicorandil + Glibenclamide 1.47±0.07* 21.88±0.48* 14.88±0.61*
Notes: * - p<0.05 in comparison with pregnant intact females; y- p<0.05 in comparison with L-NAME group.
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large omentum and an increase in the NO-synthesising 
function of the endothelium. The morphological exami­
nation of the kidneys and placenta revealed moderately 
pronounced pathological changes of a functional nature.
One of the mechanisms for preventing the develop­
ment of morphofunctional disorders in ADMA-like pree­
clampsia by resveratol is its pronounced endothelial-pro­
tective properties (Kochkarov 2009). Another positive 
aspect is an antisense activity in resveratrol (Camont et 
al. 2010, Camont et al. 2012). By reducing the number 
of free radicals, it thereby increases the bioavailability of 
the NO formed. An equally important endotheletoprotec- 
tive mechanism is an ability of resveratrol to increase the 
activity of NO-synthase, promoting greater formation of 
NO and a subsequent increase in the level of cGMP that 
leads to vasodilation (Leikert et al. 2002, Wallerath et al. 
2002). Under the conditions of oxidative stress, resver­
atrol restores the activity of DDAH, which is an enzyme 
metabolising ADMA (Frombaum et al. 2011). This is of 
great importance, since an increase in ADMA inhibits 
eNOS and contributes to an impaired endothelial function 
(Bivalacqua et al. 2001, White et al. 2006).
The ability of resveratrol to induce a dose-dependent 
relaxation in isolated strips of the pregnant uterus myo­
metrium, which is realised through K+ATP channels (Rose 
et al. 2014), plays an important role, since relaxation of 
the myometrium helps improve microcirculation in it.
Against the background of the significant complex 
protective effect of resveratrol on the development of 
morphofunctional disturbances arising when modelling 
ADMA-like preeclampsia, the lack of its positive effect on 
the coefficient of endothelial dysfunction was somewhat 
unexpected for the authors, especially as in the model of 
ADMA-like pathology in males, there was a significant de­
crease in CED (Kochkarov 2009). We believe that this fact 
can be explained by an increased gestogenic background 
in pregnant females, with which resveratrol, being a phy­
toestrogen, enters into some antagonistic relationships.
The administration of nicorondil led to a statistically 
significant decrease in diastolic pressure and CED, an in­
crease in the microcirculation in the placenta, a decrease 
in the protein content in the urine and swelling of the large 
omentum and an increase in the NO-synthesising functi­
on of the endothelium. The morphological examination of 
the kidneys and placenta revealed moderately pronounced 
pathological changes of a functional nature.
The pronounced protective effects of nicorandil are 
linked to its ability to activate K+ATP channels and to be 
a donor of nitric oxide (Tanaka et al. 2010, Gayet et al. 
2011, Holzmann 1983). Activation of K+ATP channels leads 
to hyperpolarisation of the membrane, reduction of Ca2+ 
current and relaxation of small arterial vessels. Vasodilati­
on is also facilitated by the formation of NO by activating 
guanylate cyclase (Tanaka et al. 2010, Wei et al. 2016). In 
addition, the positive effects of nicorandil are enhanced by 
its having a preconditioning effect (Belousov 2012), endo­
thelium-protective properties (Malysheva et al. 2011) and 
its ability to reduce apoptosis (Staroseltseva 2012).
A certain role in the positive effects of nicorandil can 
be played by its having an anti-inflammatory activity (Li 
et al. 2015, Serizawa et al. 2014, Chao et al. 2016). In 
addition, the ability of nicorandil to relax isolated strips 
of myomentry of the pregnant uterus, which is realised 
through K+ATP channels, can improve microcirculation in 
the placenta (Matsui et al. 2015, Hong et al. 2016).
Thus, the use of drugs possessing preconditioning 
properties for correcting morphofunctional disorders in 
ADMA-like preeclampsia leads to pronounced positive 
effects, which indicates the correctness of the chosen ap­
proach.
The administration of the tested pharmacological 
agents in combination with a prolonged form of the an­
tagonist of the Ca2+-channels of the dihydropyridine se­
ries of amlodipine led to a more significant correction of 
morphofunctional disorders in ADMA-like preeclampsia. 
This can be explained by the fact that amlodipine has its 
own endothelium-protective activity, which is fulfilled 
through the mechanisms different from those in the tested 
drugs. There are published data on the improvement of 
endothelium-dependent vasodilation due to an increased 
level of NO (Parimala et al. 2006) and an increased level 
of endothelial NO synthase (Parimala et al. 2006, Koro- 
kin et al. 2011, Xu et al. 2016). Besides, Ca2+ antagonists 
have an angioprotective effect due to a decrease in Ca2+ 
current through L-channels.
Thus, administration of drugs with different mechanis­
ms of action to animals with ADMA-like preeclampsia 
leads to more significant protective effects compared to 
those in the groups in which these drugs were used in the 
monotherapy. It becomes clear that the use of new phar­
macological agents for treating preeclampsia is most ap­
propriate with the drugs within the standard therapy.
The available information on the ability of resveratrol 
and nicorandil to activate K+ATP channels logically pre­
determined the positive effects of their use in correcting 
morphofunctional disorders in ADMA-like preeclampsia. 
It is clear that the improvement of microcirculation due to 
a reduced tone of the myointrium and the preconditioning 
effect indirectly improves the endothelial function by re­
ducing placental ischemia. However, the drugs under stu­
dy have a whole spectrum of biological activities that can 
also bring about positive effects. Therefore, a further series 
of our experiments were aimed at elucidating the role of 
K+ATP channels in the mechanism of protective effects of 
resveratrol and nicorandil in ADMA-like preeclampsia.
To determine the role of K+ATP channels in revealing the 
positive effects of the tested pharmacological agents, we 
used a blocker of these channels -  glibenclamide.
The administration of glibenclamide in combination 
with resveratrol and nicorandil significantly reduced the 
effectiveness of these drugs, but not completely. Thus, 
the results of the series of experiments make it possible 
to conclude that K+ATP channels play a significant role in 
revealing the positive effects of resveratrol and nicorandil 
in correcting morphofunctional disorders in ADMA-like 
preeclampsia, but do not completely determine them.
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